-
Publication Venue For
-
Access to technology to support telehealth in areas without specialty care for liver disease..
77:176-185.
2023
-
Contemporary management of pain in cirrhosis: Toward precision therapy for pain..
77:290-304.
2023
-
IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH..
77:20-32.
2023
-
Zac1 and the Imprinted Gene Network program juvenile NAFLD in response to maternal metabolic syndrome..
76:1090-1104.
2022
-
Changes in serum hepatitis B surface and e antigen, interferon-inducible protein 10, and aminotransferase levels during combination therapy of immune-tolerant chronic hepatitis B..
76:775-787.
2022
-
AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury.
2022
-
A revised electronic version of RUCAM for the diagnosis of DILI..
76:18-31.
2022
-
Improving the fitness of the NASH clinical trial: Standardizing the standard-of-care intervention..
76:12-14.
2022
-
Determinants of the severity of fatty liver diseases: Need all the pieces to solve the puzzle..
75:782-784.
2022
-
A Digital Case-Finding Algorithm for Diagnosed but Untreated Hepatitis C: A Tool for Increasing Linkage to Treatment and Cure..
74:2974-2987.
2021
-
A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study..
74:2952-2964.
2021
-
Hepatic Mitochondrial SAB Deletion or Knockdown Alleviates Diet-Induced Metabolic Syndrome, Steatohepatitis, and Hepatic Fibrosis..
74:3127-3145.
2021
-
Equitable Access to Liver Transplant: Bridging the Gaps in the Social Determinants of Health..
74:2808-2812.
2021
-
AASLD Deepens Commitment to Diversity, Equity, and Inclusion..
74:2216-2225.
2021
-
Application of Artificial Intelligence for Diagnosis and Risk Stratification in NAFLD and NASH: The State of the Art..
74:2233-2240.
2021
-
Development of Gastroenterology and Transplant Hepatology Milestones 2.0: A Guide For Programs, Faculty, and Fellows..
74:2226-2232.
2021
-
Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease..
74:1220-1233.
2021
-
A Beautiful Day in the Neighborhood: Application of Single-Cell Transcriptomics to Unravel Liver Cell Heterogeneity in Diseased Human Livers..
74:547-549.
2021
-
Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy..
73:2124-2140.
2021
-
Efficacy and Safety of Immunosuppression Withdrawal in Pediatric Liver Transplant Recipients: Moving Toward Personalized Management..
73:1985-2004.
2021
-
REPLY..
73:1625.
2021
-
A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis..
73:1105-1116.
2021
-
Identifying an Optimal Liver Frailty Index Cutoff to Predict Waitlist Mortality in Liver Transplant Candidates..
73:1132-1139.
2021
-
Addressing Social Determinants of Liver Disease During the COVID-19 Pandemic and Beyond: A Call to Action..
73:811-820.
2021
-
Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH..
73:625-643.
2021
-
Targeting Tumor-Associated Antigens in Hepatocellular Carcinoma for Immunotherapy: Past Pitfalls and Future Strategies..
73:821-832.
2021
-
Human Leukocyte Antigen B*14:01 and B*35:01 Are Associated With Trimethoprim-Sulfamethoxazole Induced Liver Injury..
73:268-281.
2021
-
Reproductive Health and Liver Disease: Practice Guidance by the American Association for the Study of Liver Diseases..
73:318-365.
2021
-
Targeting Neoantigens in Hepatocellular Carcinoma for Immunotherapy: A Futile Strategy?.
73:414-421.
2021
-
Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria..
72:2014-2028.
2020
-
Reply..
72:2241-2242.
2020
-
Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH..
72:1219-1229.
2020
-
Immunosuppression Withdrawal in Liver Transplant Recipients on Sirolimus..
72:569-583.
2020
-
Thyroid Hormones and Thyromimetics: A New Approach to Nonalcoholic Steatohepatitis?.
72:770-771.
2020
-
Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial..
72:58-71.
2020
-
A Randomized Controlled Trial of an Integrated Alcohol Reduction Intervention in Patients With Hepatitis C Infection..
71:1894-1909.
2020
-
Targeting Histone Deacetylase 6 Reprograms Interleukin-17-Producing Helper T Cell Pathogenicity and Facilitates Immunotherapies for Hepatocellular Carcinoma..
71:1967-1987.
2020
-
NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis..
71:1198-1212.
2020
-
Nonalcoholic Steatohepatitis Is Associated With Liver-Related Outcomes and All-Cause Mortality in Chronic Hepatitis B..
71:539-548.
2020
-
Reply..
71:769.
2020
-
The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials..
70:1913-1927.
2019
-
A North American Expert Opinion Statement on Sarcopenia in Liver Transplantation..
70:1816-1829.
2019
-
Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum..
70:1841-1855.
2019
-
Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps..
70:1457-1469.
2019
-
The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis..
70:788-801.
2019
-
A Roadmap for Value-Based Payment Models Among Patients With Cirrhosis..
69:1300-1305.
2019
-
Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease..
69:684-698.
2019
-
"Too Female" for Liver Transplantation..
68:2424-2425.
2018
-
Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis..
68:1646-1648.
2018
-
Stereotactic Body Radiation Therapy-Induced Abscopal Effect on Hepatocellular Carcinoma After Treatment for Lung Cancer: A Case Report..
68:1653-1655.
2018
-
Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: Results from two prospective cohort studies..
67:1797-1806.
2018
-
The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial..
67:549-559.
2018
-
Comments on cochrane review on direct-acting antivirals for hepatitis C..
66:1016-1019.
2017
-
Death and liver transplantation within 2 years of onset of drug-induced liver injury..
66:1275-1285.
2017
-
Drug rechallenge following drug-induced liver injury..
66:646-654.
2017
-
Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis..
65:1543-1556.
2017
-
Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements..
65:1267-1277.
2017
-
The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study..
64:2077-2088.
2016
-
Novel quantification of tenofovir disoproxil fumarate adherence in human immunodeficiency virus/hepatitis B coinfected patients with incomplete hepatitis B virus viral suppression..
64:999-1000.
2016
-
Reply..
64:994-995.
2016
-
A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease..
64:85-91.
2016
-
Reply..
63:1057-1058.
2016
-
The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota..
63:764-775.
2016
-
Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data..
63:437-444.
2016
-
Liver receptor homolog-1 is a critical determinant of methyl-pool metabolism..
63:95-106.
2016
-
Benzyl Alcohol: A novel treatment for acetaminophen overdose?.
62:1641-1642.
2015
-
Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus..
62:932-954.
2015
-
Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C..
62:409-416.
2015
-
Reply: To PMID 24849310..
61:1770-1771.
2015
-
Prometheus and progenitors..
61:1427-1429.
2015
-
Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients..
61:790-801.
2015
-
Reply: To PMID 24123276..
61:1094.
2015
-
Excess mortality on the liver transplant waiting list: unintended policy consequences and Model for End-Stage Liver Disease (MELD) inflation..
61:285-291.
2015
-
Treatment response in the PIVENS trial is associated with decreased Hedgehog pathway activity..
61:98-107.
2015
-
Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network..
60:1399-1408.
2014
-
Reply: To PMID 23913408..
60:1445-1446.
2014
-
The β-adrenoceptor agonist isoproterenol rescues acetaminophen-injured livers through increasing progenitor numbers by Wnt in mice..
60:1023-1034.
2014
-
Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network..
60:679-686.
2014
-
Trends in hepatitis C treatment uptake in the United States..
60:768-769.
2014
-
Prevalence and natural history of histologically proven chronic liver disease in a longitudinal cohort of patients with type 1 diabetes..
60:158-168.
2014
-
Caffeine stimulates hepatic lipid metabolism by the autophagy-lysosomal pathway in mice..
59:1366-1380.
2014
-
Hepatitis C disease severity in living versus deceased donor liver transplant recipients: an extended observation study..
59:1311-1319.
2014
-
Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease..
59:471-482.
2014
-
Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations..
59:661-670.
2014
-
Cross-talk between Notch and Hedgehog regulates hepatic stellate cell fate in mice..
58:1801-1813.
2013
-
Identification of driver genes in hepatocellular carcinoma by exome sequencing..
58:1693-1702.
2013
-
Intrapulmonary shunt confirmed by intracardiac echocardiography in the diagnosis of hepatopulmonary syndrome..
58:1514-1515.
2013
-
HINT2 and fatty liver disease: mitochondrial protein hyperacetylation gives a hint?.
57:1681-1683.
2013
-
Hedgehog pathway and pediatric nonalcoholic fatty liver disease..
57:1814-1825.
2013
-
Successful transplantation of human hepatic stem cells with restricted localization to liver using hyaluronan grafts..
57:775-784.
2013
-
Therapeutic effect of cytotoxic T lymphocyte antigen 4/immunoglobulin on a murine model of primary biliary cirrhosis..
57:708-715.
2013
-
Hepatic enrichment and activation of myeloid dendritic cells during chronic hepatitis C virus infection..
56:2071-2081.
2012
-
Lower serum hepcidin and greater parenchymal iron in nonalcoholic fatty liver disease patients with C282Y HFE mutations..
56:1730-1740.
2012
-
Intraductal papillary neoplasm of the bile duct: a biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas?.
56:1352-1360.
2012
-
Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study..
56:1311-1318.
2012
-
Higher dietary fructose is associated with impaired hepatic adenosine triphosphate homeostasis in obese individuals with type 2 diabetes..
56:952-960.
2012
-
Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response..
56:444-454.
2012
-
Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner..
56:49-56.
2012
-
Lost in translation? IL28B's discovery and the journey back to the patient..
56:5-8.
2012
-
Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease..
55:1711-1721.
2012
-
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association..
55:2005-2023.
2012
-
After goodbye? Dead hepatocytes as a biomarker for fibrosis and steatohepatitis..
55:333-335.
2012
-
Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response..
54:1538-1546.
2011
-
Up-regulation of Hedgehog pathway is associated with cellular permissiveness for hepatitis C virus replication..
54:1580-1590.
2011
-
Biomarkers of liver fibrosis: what lies beneath the receiver operating characteristic curve?.
54:1454-1462.
2011
-
Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era..
54:1313-1321.
2011
-
The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury..
54:931-939.
2011
-
Racial differences in hepatitis C treatment eligibility..
54:70-78.
2011
-
High predictive accuracy of an unbiased proteomic profile for sustained virologic response in chronic hepatitis C patients..
53:1809-1818.
2011
-
Hedgehog activity, epithelial-mesenchymal transitions, and biliary dysmorphogenesis in biliary atresia..
53:1246-1258.
2011
-
Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR..
53:389-395.
2011
-
Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model..
53:483-492.
2011
-
Lineage restriction of human hepatic stem cells to mature fates is made efficient by tissue-specific biomatrix scaffolds..
53:293-305.
2011
-
Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis..
53:106-115.
2011
-
Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotype..
52:2243-2244.
2010
-
IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C..
52:1888-1896.
2010
-
Mitochondrial and immunoallergic injury increase risk of positive drug rechallenge after drug-induced liver injury: a systematic review..
52:2216-2222.
2010
-
Overlapping high-resolution copy number alterations in cancer genomes identified putative cancer genes in hepatocellular carcinoma..
52:1690-1701.
2010
-
Paracrine signals from mesenchymal cell populations govern the expansion and differentiation of human hepatic stem cells to adult liver fates..
52:1443-1454.
2010
-
Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C..
52:1208-1215.
2010
-
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease..
52:913-924.
2010
-
Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection..
52:822-832.
2010
-
Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy..
52:864-874.
2010
-
Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: implications for the pathogenesis of HIV/hepatitis C virus-induced liver fibrosis..
52:612-622.
2010
-
Activation of Rac1 promotes hedgehog-mediated acquisition of the myofibroblastic phenotype in rat and human hepatic stellate cells..
52:278-290.
2010
-
Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease..
51:1998-2007.
2010
-
Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease..
51:1961-1971.
2010
-
Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection..
51:1904-1911.
2010
-
Hedgehog signaling is critical for normal liver regeneration after partial hepatectomy in mice..
51:1712-1723.
2010
-
Liver cancer: EphrinA2 promotes tumorigenicity through Rac1/Akt/NF-kappaB signaling pathway..
51:535-544.
2010
-
Epithelial-to-mesenchymal transitions in the liver..
50:2007-2013.
2009
-
Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis..
50:1421-1430.
2009
-
Does hepatitis B surface antigen kinetics, including both decline and reaching a threshold, improve prediction of response?.
50:1314.
2009
-
Repair-related activation of hedgehog signaling promotes cholangiocyte chemokine production..
50:518-527.
2009
-
Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the nonalcoholic steatohepatitis clinical research network..
49:1904-1912.
2009
-
Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States..
49:1563-1570.
2009
-
Liver biopsy..
49:1017-1044.
2009
-
Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network..
49:809-820.
2009
-
Hepatitis B virus viral load and treatment decision..
49:699.
2009
-
Recruitment of host progenitor cells in rat liver transplants..
49:587-597.
2009
-
Phosphatase and tensin homolog (PTEN) regulates hepatic lipogenesis, microsomal triglyceride transfer protein, and the secretion of apolipoprotein B-containing lipoproteins..
48:1799-1809.
2008
-
Surveillance for hepatocellular carcinoma in patients with primary biliary cirrhosis..
48:1149-1156.
2008
-
Diacylglycerol acyltranferase 1 anti-sense oligonucleotides reduce hepatic fibrosis in mice with nonalcoholic steatohepatitis..
47:625-635.
2008
-
Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus..
46:1341-1349.
2007
-
Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis.
2022
-
Development and validation of a primary sclerosing cholangitis-specific patient-reported outcomes instrument: The PSC PRO.
2018
-
Hedgehog regulates yes-associated protein 1 in regenerating mouse liver.
2016
-
To transfuse or not to transfuse in upper gastrointestinal hemorrhage? That is the question.
2014
-
Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis.
2014